Myofibroblastický nádor jícnu – kazuistika, dlouhodobý follow-up a přehled literatury

Download PDF English version

Authors: J. Vaculová ¹; Jiří Dolina ¹; P. Jabandžiev ^2,3; M. Štěrba ²; J. Tůma ⁴; R. Doušek ⁴; L. Plánka ⁴; J. Šenkyřík ⁵; J. Štěrba ⁶; V. Bajčiová ⁶; M. Eid ⁷; Z. Pavlovský ⁸; Z. Kala ⁹; L. Kunovsky ^1,9
Authors‘ workplace: Department of Gastroenterology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic ¹; Department of Pediatrics, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic ²; Central European Institute of Technology, Masaryk University, Brno, Czech Republic ³; Department of Pediatric Surgery, Orthopedics and Traumatology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic ⁴; Department of Pediatric Radiology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic ⁵; Department of Pediatric Oncology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic ⁶; Department of Hematology, Oncology and Internal Medicine, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic ⁷; Department of Pathology, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic ⁸; Department of Surgery, University Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic ⁹
Published in: Klin Onkol 2021; 34(4): 313-318
Category: Case Report
doi: https://doi.org/10.48095/ccko2021313

Overview

Východiska: Zánětlivý myofibroblastický nádor jícnu je vzácná mezenchymální neoplazie středně maligního potenciálu. Přestože se nejčastěji vyskytuje v plicích, může se objevit v mnoha jiných anatomických lokalizacích vč. gastrointestinálního traktu, avšak postižení jícnu je velmi vzácné. Myofibroblastický nádor jícnu se nejčastěji manifestuje u dětí a mladých dospělých. Základním terapeutickým postupem je chirurgická resekce. Kazuistika: V této kazuistice prezentujeme případ 13letého chlapce s myofibroblastickým nádorem jícnu, který podstoupil chirurgickou resekci v roce 2013 a od té doby je v trvalé remisi. Závěr: Chirurgická léčba je nejvíce upřednostňovanou metodou léčby. V případě kompletní resekce je riziko recidivy nízké. Nicméně každého pacienta po resekci je třeba pečlivě dispenzarizovat.

Klíčová slova:

zánětlivý pseudotumor – karcinom jícnu – myofibroblastický tumor – granulom z plazmatických buněk – endoskopie – chirurgie

Sources

1. Kovach SJ, Fischer AC, Katzman PJ et al. Inflammatory myofibroblastic tumors. J Surg Oncol 2006; 94 (5): 385–391. doi: 10.1002/jso.20516.

2. Attili SV, Chandra CR, Hemant DK et al. Retroperitoneal inflammatory myofibroblastic tumor. World J Surg Oncol 2005; 3: 66. doi: 10.1186/1477-7819-3-66.

3. Chen Y, Tang Y, Li H et al. Inflammatory myofibroblastic tumor of the esophagus. Ann Thorac Surg 2010; 89 (2): 607–610. doi: 10.1016/j.athoracsur.2009.07.091.

4. Kurihara K, Mizuseki K, Ichikawa M et al. Esophageal inflammatory pseudotumor mimicking malignancy. Intern Med 2001; 40 (1): 18–22. doi: 10.2169/internalmedicine.40.18.

5. Privette A, Fisk P, Leavitt B et al. Inflammatory miofibroblastic tumor presenting with esopageal obstruction and an inflammatory syndrome. The annals of thoracic surgery 2008; 86 (4): 1364–1367. doi: 10.1016/j.athoracsur.2008.03.056.

6. Jayarajah U, Bulathsingala RP, Sumana Handagala DM et al. Inflammatory miofibroblastic tumor of the oesophagus presenting with hematemesis and maelena: a case report and review of literatue. Clin Case Rep 2017: 6 (1): 82–85. doi: 10.1002/ccr3.1296.

7. Savvidou OD, Sakellariou VI, Papakonstantinou O et al. Inflammatory myofibroblastic tumor of the thigh: presentation of a rare case and review of the literature. Case Rep Orthop 2015; 2015: 814241. doi: 10.1155/2015/814241.

8. Coffin CM, Hornick JL, Fletcher CD. Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases. Am J Surg Pathol 2007; 31 (4): 509–520. doi: 10.1097/01.pas.0000213393.57322.c7.

9. Palaskar S, Koshti S, Maralingannavar M et al. Inflammatory myofibroblastic tumor. Contemt Clin Dent 2011: 2 (4): 274–277. doi: 10.4103/0976-237X.91787.

10. Marchi S, Costa F, Mumolo MG et al. Post-traumatic inflammatory pseudotumor of the esophagus. Gastrointest Endosc 2001; 54 (3): 397–399. doi: 10.1067/ mge.2001.116324.

11. Dousek R, Tuma J, Planka L et al. Inflammatory myofibroblastic tumor of the esophagus in childhood: a case report and a review of the literature. J Pediatr Hematol Oncol 2015; 37 (2): e121–124. doi: 10.1097/MPH. 0000000000000275.

12. Bjelovic M, Micev M, Spica B et al. Primary inflammatory myofibroblastic tumor of the stomach in an adult woman: a case report and review of the literature. World J Surg Oncol 2013; 11: 35. doi: 10.1186/1477-7819- 11-35.

13. Inamdar AA, Pulinthanathu R. Malignant transformation of inflammatory myofibroblastic tumor of urinary bladder: A rare case scenario. Bladder (San Franc) 2019; 6 (2): e39. doi: 10.14440/bladder.2019.805.

14. Pettinato G, Manivel JC, De Rosa N et al. Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations. Am J Clin Pathol 1990; 94 (5): 538–546. doi: 10.1093/ajcp/94.5.538.

15. Lewin K, Appelman H. Tumor of the esophagus and stomach, third series. Washington DC: Armed Forces Institute of Pathology 1996: 145–161.

16. Kim YI, Kim WH. Inflammatory fibroid polyp of gastrointestinal tract. Am J Clin Pathol 1988; 89 (6): 721–727. doi: 10.1093/ajcp/89.6.721.

17. Watanabe H, Jass JR, Sabin LH. Tumor-like lesions, in Histological Typing of Oesophageal and Gastric Tumours. 2nd ed. Berlin: Springer-Verlag 1990: 16–17.

18. Lovly CM, Gupta A, Lipson D et al. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions. Cancer Discov 2014; 4 (8): 889–895. doi: 10.1158/2159-8290.CD-14-0377.

19. Mossé YP, Voss SD, Lim MS et al. Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children‘s oncology group study. J Clin Oncol 2017; 35: 3215–3221.

20. Khakural P, Sapkota R, Shrestha UK et al. Successful surgical management of a rare esophageal inflammatory myofibroblastic tumour: a case report. J Cardiothorac Surg 2015; 10: 112. doi: 10.1186/s13019-015-0327-5.

21. Seco JL, Claver M, Bengoechea M et al. Plasma cell granuloma of the distal oesophagus. Br J Surg 1990; 77 (9): 996–997. doi: 10.1002/bjs.1800770912.

22. Goldin SB, Osborne D, Paidas C et al. Inflammatory myofibroblastic tumor of the midesophagus. Fetal Pediatr Pathol 2007; 26 (5–6): 243–254. doi: 10.1080/15513810801893421.

23. SantaCruz KS, McKinley ET, Powell RD Jr et al. Inflammatory myofibroblastic tumor of the gastroesophageal junction in childhood. Pediatr Pathol Mol Med 2002; 21 (1): 49–56. doi: 10.1080/pdp.21.1.49.56.

24. Li J, Liu F, Wang Z et al. Inflammatory pseudotumor of the esophagus—GI image. J Gastrointest Surg 2010; 14 (1): 195–198. doi: 10.1007/s11605-009-0893-8.

25. Shaw AT, Ou SH, Bang YJ et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014; 371 (21): 1963–1971. doi: 10.1056/NEJMoa1406766.

26. Zhang N, Zeng Q, Chen C et al. Clinical characteristics and prognosis of pulmonary inflammatory myofibroblastic tumor: an over 10-year retrospective analysis. Pediatr Investig 2020; 4 (3): 192–197. doi: 10.1002/ped4.12218.

27. Song W, Zhu Y. Clinical characteristics and outcomes of 17 cases of inflammatory myofibroblastic tumor at a University Hospital in China. Oncol Lett 2021; 21 (1): 51. doi: 10.3892/ol.2020.12312.

28. Casanova M, Brennan B, Alaggio R et al. Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG). Eur J Cancer 2020; 127: 123–129. doi: 10.1016/j.ejca.2019.12.021.

29. Lu CH, Huang HY, Chen HK et al. Huge pelvic-abdominal malignant inflammatory myofibroblastic tumor with rapid recurrence in a 14-year-old boy. World J Gastroenterol 2010; 16 (21): 2698–2701. doi: 10.3748/wjg.v16.i21.2698.